Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
12
×
san francisco top stories
12
×
san francisco blog main
biotech
boston blog main
boston top stories
new york top stories
clinical trials
new york blog main
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
roche
cancer
europe top stories
fda
novartis
cancer drugs
deals
eli lilly
europe blog main
genentech
investing
What
drug
12
×
cancer
fda
medicines
approval
bio
medicine
new
patients
pricing
roundup
therapy
approved
blueprint
ceo
cholesterol
friday
immunotherapy
lowering
market
marketing
oral
plan
ret
roche
week
aces
acquisitions
address
advanced
advantages
agency
aimmune
allergy
anathema
announced
approves
arrival
atrophy
awaited
Language
unset
12
×
Current search:
drug
×
unset
×
" national top stories "
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)